First clinical results with αβ+ T-cell depleted haploidentical stem cells in children Children’s University Hospital, Tübingen, Germany P Lang, T Feuchtinger,

Slides:



Advertisements
Similar presentations
Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.
Advertisements

台北榮總血液腫瘤科 楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.
Blood and Marrow Transplant: The basics…what you need to know Resident Education Lecture Series.
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
Bone Marrow Transplantation. Unlike solid organ transplant, in bone marrow transplantation (BMT) the immunology goes two ways. There is host vs. ​ graft.
NK cell therapy after transplantation Miltenyi Satellite Symposium
CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.
Allogeneic Stem Cell Transplantation: The Journey
New Strategies for the Prevention and Treatment of Graft vs. Host Disease (GVHD) Simrit Parmar, MD Stem Cell Transplant & Cellular Therapy BTG2013, Hong.
POSTER TEMPLATE BY: Features of Epstein Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) unrelated.
Graft vs Host Disease Remains the major cause of treatment related morbidity and mortality in allogeneic HCT. Caused by donor derived alloreactive T cells.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
1 Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée Marseille, France ALLOGENEIC STEM CELL TRANSPLANTATION.
What is the Expected Clinical Outcome after BMT ?.
2 nd International Conference on Hematology & Blood Disorders ( Sep. 29-Oct. 01, 2014 Baltimore, USA ) Hyogo College of Medicine Graft-versus-GVHD, a second.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
G. S / AIH 2006 Graft-versus-Host disease Physiopathology Gérard Socié, MD PhD Hospital Saint Louis Translating experimental into clinical knowledge.
BENIN BLOOD & MARROW TRANSPLANT SOCIETY OF NIGERIA JULY STEM CELL TRANSPLANT CENTRE, BENIN Graft versus Host Disease in HSCT Anthony Oyekunle.
Immunotherapy (Cancer therapy with T-Cells)
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Pavan Kumar Bhamidipati 1, John F. DiPersio 1, Keith Stockerl-Goldstein 1, Geoffrey L. Uy 1, Peter Westervelt 1, Feng Gao 2, Ravi Vij 1, Mark A. Schroeder.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Natural Killer Cells:
Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies.
Time to neutrophil engraftment Time to platelet engraftment
Table S1: Antibodies Used for Flow Cytometric Analysis
Per microtrasplantation
Supplemental table 1 Patients' characteristics Variables Number
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,
Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Introduction Imagine result Case Report Comment
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
Expert Perspectives on HSCT: Planning for Success
Whom should you refer for allogeneic transplantation?
Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen– Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up.
Ematologia, Ospedali Riuniti, Bergamo
The role of allogeneic transplantation in peripheral T-cell lymphomas
Haploidentical BMT with Post Transplant Cyclophosphamide
R. Handgretinger, X. Chen, M. Pfeiffer, M. Schumm, I. Mueller, T
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Cord blood transplantation and stem cell regenerative potential
Figure 2 Components of each transplantation platform
Letermovir(Prevymis™) Guidelines for Inpatient Use
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children  Matthias Eyrich, Gernot.
Hematopoietic Stem Cell Transplantation for Patients with AML
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial 
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey 
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.
Fig. 1 HSCT: A platform for cellular therapies.
Is KIR- typing relevant to HCT donor selection?
The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion 
by Rupert Handgretinger, Peter Lang, and Maya C. André
Stem Cell Transplant for Myeloid Neoplasms
Clinical Lymphoma, Myeloma and Leukemia
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,
Bridge to transplant following Bv+Bs regimen.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Frédéric Baron, Rainer Storb 
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Anti-PD-1H Antibody Prevents Graft Versus Host Disease
Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation  Abir Bhattacharyya, Laïla-Aïcha.
Volume 24, Issue 9, Pages (September 2016)
Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.
Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy- alone conditioning regimen  J.F Lacerda, C Martins, J.A Carmo,
Presentation transcript:

First clinical results with αβ+ T-cell depleted haploidentical stem cells in children Children’s University Hospital, Tübingen, Germany P Lang, T Feuchtinger, HM Teltschik, P Schlegel, M Schumm, P Schwarze, M Pfeiffer, K Schilbach, R Handgretinger

Haploidentical donors : T cell depletion mandatory 1.CD34+ Selection „pure stem cells“ 2. CD3/19 Depletion Stem cells + effectors (NK cells) 3. TCRαβ/CD19 Depletion Stem cells + effectors (NK cells + γδT cells) 4. Antigen- specific T cells

The anti-leukemic activity of gamma/delta T-cells Otto M. et al: Human γδT cells from G-CSF mobilized donors retain strong tumoricidal activity and produce immunostimulatory cytokines after clinical scale isolation. J Immunotherapy 2005: 28: 73 Godder et al., Long term disease-free survival in acute leukemic patients recovering with increased γδT cells after partially mismatched related donor bone marrow transplantation. BMT 2007; 39,

magnet waste (  T cells) 1. biotin-anti-  mAb 2. microbeads with anti-biotin mAb graft  T-cells CD34+ and CD34- progenitors NK cells dendritic cells Strategy for depletion of  + T-cells Chaleff S. et al.: A large scale method for the selective Depletion of  /  T-lymphocytes from PBSC for allogeneic Transplantation. Cytotherapy, 2007

TCR  depletion: Efficacy of procedure n = 9BeforeAfterLog Depletion Percent TCR  29.2 ± ± absolute TCR  ± 0.52 x ,38 ± 0.22 x ± 0.3 absolute CD ± 0.44 x ± 1.8 x ± 0.2 absolute CD ± 1.4 x ± 5.8 x ± 0.6

n=49 Comparative analysis of the efficacy of T-cell depletion CD34+ selection vs CD3- vs TcR  -depletion 4.6 log

Graft composition after TCR  /CD19 depletion (n=24 patients) CD34+ x10 6 /kg CD3+ x106/kg CD19+ x10 3 /kg CD56+ x10 6 /kg CD14+ x10 6 /kg aßTcR+ x10 3 /kg  TcR+ x10 6 /kg min max median

Patients (pediatric, n=24) Diagnosisn= ALL12 AML/MDS/JMML7 Nonmalignant4 Solid tumors1 Disease statusn= CR2-CR68 (35%) NR/active disease11 (48%) 2 nd /3 rd SCT16 (70%)

ATG-F (15 mg/kg) 1mg4 mg5 mg Fludarabin (mg/m²) or Clofarabin 40mg Thiotepa (mg/kg) 10mg Melphalan (mg/m²) 70mg TCR  /CD19 depleted cells days from transplantation Conditioning regimen (2) n=12 steroids MMF, if > residual abT cells

TCR  /CD19 Depletion: Engraftment

TCR  /CD19 Depletion: residual  T-cells do not cause GvHD (22/24 patients without pharmacological immune suppression) acute GvHD graden=% no GvHD521 °11250 °2312 °3312 °414

TCR  /CD19 Depletion: Outcome  Alive: 17 out of 24 patients (70%)  Median Follow up: 0.5 ( ) years

Comparison of CD3+ recovery: CD3/19 vs TCR  /CD19 Depletion

Comparison of CD3+ recovery at day +30 p< CD3/19 n = 45 TcRab n = 19

Comparison of CD3+ recovery: CD3/19 vs TCR  /CD19 Depletion p<0.01

T cell recovery after TCR  Depletion

TCR  -Depletion results in grafts with high numbers of effector cells (  T cells, NK cells) Robust engraftment Profound depletion of  T cells: prevents GvHD in HLA mismatched trp Immune recovery seems to be signifcantly faster than after other graft manipulation procedures Conclusions

University Children´s Hospital Tübingen: Tobias Feuchtinger Heiko-Manuel Teltschik Michael Schumm Patrick Schlegel Matthias Pfeiffer Philip Schwarze Martin Ebinger Karin Schilbach Rupert Handgretinger